Actively Recruiting
Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome
Led by POLYSAN Scientific & Technological Pharmaceutical Company · Updated on 2025-04-06
90
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Post intensive care syndrome (PIC syndrome) is an important problem in modern intensive care strategy. Understanding the mechanisms of PIC syndrome helps prevent it in patients with respiratory, neuromuscular transmission, and cognitive impairments that require prolonged support of vital functions. Significant role in the formation and severity of PIC syndrome is played by the severity of the systemic inflammatory response, which is an individual reaction of the body, and this determines the degree of neurological and psychological deficits. Chronic diseases such as diabetes mellitus, especially in the context of metabolic syndrome, worsen the course of PIC syndrome and delays recovery. Early initiation of rehabilitation measures in the intensive care unit and subsequent expansion of the individual rehabilitation program contributes to the rapid and successful recovery of not only vital functions, but also cognitive, motor and emotional disorders. This shortens the hospital stay of patient and improves their quality of life after discharge.
CONDITIONS
Official Title
Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 18 years or older
- Stayed in the intensive care unit for 3 days or more
- Diagnosed with post intensive care syndrome (PIC syndrome) of moderate to severe severity (3 to 6 points)
- Diagnosed with critical illness polyneuropathy, respiratory neuropathy, or dysphagia at rehabilitation stages 2-3 with any PIC syndrome severity
- Diagnosed with decreased gravitational gradient or decreased exercise tolerance at rehabilitation stages 2-3 with any PIC syndrome severity
You will not qualify if you...
- Premorbid vital activity level of 4-5 points on the rehabilitation routing scale
- Hematocrit 30% or lower
- Hemoglobin level 80 g/L or lower
- Acute cardiac failure
- Acute respiratory failure
- Acute renal failure
- Acute liver cell failure
- Use of metabolic agent drugs at the time of study inclusion
- Life expectancy of 6 months or less or incurable diseases in decompensated stage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brain Institute Clinic
Yekaterinburg, Sverdlovsk Oblast, Russia, 623702
Actively Recruiting
Research Team
A
Andrey Belkin, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here